European Association for the Study of the Liver (EASL) International Liver Congress (ILC)

At this year’s International Liver Conference, PathAI will be sharing three posters featuring new research and innovative applications of AI-powered digital pathology in NASH. The abstracts detail results from a retrospective analysis of liver biopsies from a Phase 2 trial of resmetirom (in partnership with Madrigal Pharmaceuticals), the ability of continuous fibrosis scoring to predict progression (in partnership with Gilead Sciences), and a novel imaging method for detecting and quantifying fibrosis.



June 22 – 26, 2022

London, United Kingdom
Contact Us  | Learn More


PathAI Poster Presentations

Machine Learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis

Developed in partnership with Gilead Sciences, Inc

Presenter: Janani Iyer, PhD

Session Date and Time: June 25, 2022, 9:00 – 18:00
Poster Session: NAFLD: Experimental and pathophysiology
Abstract #3788
View Abstract

Retrospective AI-based Measurement of NASH Histology (AIM-NASH) analysis of biopsies from Phase 2 study of Resmetirom confirms significant treatment-induced changes in histologic features of non-alcoholic steatohepatitis

Developed in partnership with Madrigal Pharmaceuticals

Presenter: Janani Iyer, PhD

Session Date and Time: June 25, 2022, 9:00 – 18:00
Poster Session: NAFLD: Experimental and pathophysiology
Abstract #3625
View Abstract

Quantitative multimodal anisotropy imaging enables automated fibrosis assessment of H&E-stained tissue

Presenter: Justin Lee, PhD

Session Date and Time: June 25, 2022, 9:00 – 18:00
Poster Session:
NAFLD: Experimental and pathophysiology
Abstract #3370
View Abstract